Halozyme Therapeutics Inc (HALO)
Current ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total current assets | US$ in thousands | 1,085,340 | 1,126,980 | 987,797 | 873,584 | 746,424 | 879,006 | 765,745 | 615,019 | 739,013 | 653,201 | 541,938 | 988,689 | 926,287 | 1,017,300 | 999,750 | 941,719 | 554,764 | 498,895 | 500,358 | 467,971 |
Total current liabilities | US$ in thousands | 139,100 | 108,815 | 133,360 | 131,639 | 112,494 | 115,185 | 116,393 | 91,919 | 130,789 | 109,384 | 199,512 | 111,691 | 117,147 | 113,153 | 114,251 | 107,421 | 421,385 | 26,976 | 26,073 | 42,002 |
Current ratio | 7.80 | 10.36 | 7.41 | 6.64 | 6.64 | 7.63 | 6.58 | 6.69 | 5.65 | 5.97 | 2.72 | 8.85 | 7.91 | 8.99 | 8.75 | 8.77 | 1.32 | 18.49 | 19.19 | 11.14 |
December 31, 2024 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $1,085,340K ÷ $139,100K
= 7.80
The current ratio of Halozyme Therapeutics Inc has exhibited significant fluctuations over the periods reported. The current ratio measures the company's ability to cover its short-term liabilities with its current assets.
From December 31, 2020, to June 30, 2021, the current ratio declined sharply from 1.32 to 8.75, indicating a significant improvement in the company's short-term liquidity position.
Over the subsequent quarters, the current ratio ranged between 5.65 and 8.99, reflecting relatively stable liquidity levels. However, there was a notable decrease in the current ratio to 2.72 on June 30, 2022, signaling a potential deterioration in the company's ability to meet its short-term obligations with current assets.
The current ratio improved from September 30, 2022, to September 30, 2024, reaching a peak of 10.36 on September 30, 2024, suggesting a strengthened short-term liquidity position during this period.
It is important for investors and stakeholders to closely monitor the current ratio of Halozyme Therapeutics Inc to assess its liquidity risk and financial stability. Fluctuations in the current ratio may indicate changes in the company's ability to manage its short-term obligations effectively.
Peer comparison
Dec 31, 2024